Recent advancements in AD research have shown that commercially available blood‐based biomarkers can identify AD pathology with high accuracy and before the onset of cognitive symptoms. 39 Our work identifies when structural MRI changes in hippocampal volume associated with APOE genotype, a later disease stage biomarker, can be detected. These findings suggest that biomarker testing should begin earlier for ε3/ε4 and ε4/ε4 carriers compared to ε3/ε3 carriers. Integrating information from these different modalities could improve screening, diagnostic accuracy, and disease monitoring, facilitating timely and personalized prevention and treatment interventions.
